Orasure Technologies (OSUR) AI Stock Analysis

• Market Cap: $214.68M
• Dividend Yield: N/A
• Average Volume (3M): 820.34K
• Price to Earnings (P/E): 25.3
• Beta (1Y): 0.56
• Revenue Growth: -46.95%
• EPS Growth: -237.44%
• Country: US
• Employees: 501
• Sector: Healthcare
• Sector Strength: 46
• Industry: Medical - Instruments & Supplies
• EPS (TTM): -0.21
• Shares Outstanding: 74,800,130
• 10 Day Avg. Volume: 896,991
• 30 Day Avg. Volume: 820,344
• PEG Ratio: -0.60
• Price to Book (P/B): 1.64
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -7.49
• Enterprise Value/Market Cap: 1.98
• Enterprise Value/Revenue: 0.61
• Enterprise Value/Gross Profit: 6.31
• Enterprise Value/Ebitda: 57.20
• 1Y Price Target: $3.00
• Price Target Upside: -0.66% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 1

• Rating: 57 Neutral
• Price Target: $3.00 ▼(-0.66%Downside)

Orasure Technologies' overall stock score reflects a challenging financial performance due to declining revenues and profitability. Technical indicators show short-term stability, but valuation concerns remain with a negative P/E ratio. Despite some positive steps from the earnings call, significant headwinds persist, impacting the overall score.

Orasure Technologies Business Overview & Revenue Model

Company Description

OraSure Technologies, Inc., together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, Diagnostics and Molecular Solutions. The company's principal products include InteliSwab COVID-19 rapid test, InteliSwab COVID-19 rapid test pro, InteliSwab COVID-19 rapid test rx, OraQuick Rapid HIV test, OraQuick In-Home HIV test, OraQuick HIV self-test, OraQuick HCV rapid antibody test, OraQuick Ebola rapid antigen test, OraSure oral fluid collection device used in conjunction with screening and confirmatory tests for HIV-1 antibodies; Intercept drug testing systems; immunoassay tests and reagents; and Q.E.D. saliva alcohol test. It also offers genomic products under the Oragene and ORAcollect brands; microbiome collection products; and GenoFIND genomics laboratory services. In addition, the company provides ORAcollect, RNA and OMNIgene, and RAL collection devices for use in connection with COVID-19 molecular testing; offers Colli-Pee collection device for the volumetric collection of first void urine; and manufactures and sells kits that are used to collect, stabilize, transport, and store samples of genetic material for molecular testing in the academic research and commercial applications, including ancestry, disease risk management, lifestyle, and animal testing. Further, it provides other diagnostic products, such as immunoassays and other in vitro diagnostic tests. The company markets its products to clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies, Inc. was incorporated in 2000 and is headquartered in Bethlehem, Pennsylvania.

How the Company Makes Money

OraSure Technologies generates revenue primarily through the sale of its diagnostic products and services. The company markets its rapid diagnostic test kits to healthcare providers, government agencies, and consumers. A significant portion of its earnings comes from its flagship products like the OraQuick HIV and OraQuick HCV tests, which are widely used for public health screening. Additionally, OraSure earns revenue from its DNA Genotek subsidiary, which provides sample collection kits for genetic research and testing. The company's business model is further supported by strategic partnerships with government health organizations and research institutions, as well as licensing agreements and collaborations with other healthcare companies.

Orasure Technologies Financial Statement Overview

Summary

Orasure Technologies is facing financial challenges with declining revenues and profitability. Despite a strong balance sheet with low debt levels, the company struggles with negative profitability and cash flow issues, indicating operational inefficiencies and the need for better revenue growth and cost management.

Income Statement

Orasure Technologies has faced challenges in its income statement with declining revenues and profitability. The TTM (Trailing-Twelve-Months) shows a net loss with negative EBIT and EBITDA margins, indicating operational inefficiencies. Revenue growth has been erratic, with recent declines, suggesting volatility in sales performance.

Balance Sheet

The balance sheet of Orasure Technologies is relatively strong, with a high equity ratio and low debt levels. The company's debt-to-equity ratio is low, implying low financial leverage and risk. However, despite strong equity, the return on equity is negative, highlighting the impact of ongoing losses.

Cash Flow

Cash flow analysis reveals a mixed picture. The company has generated positive operating cash flow in the TTM, but free cash flow has turned negative due to capital expenditures. The free cash flow to net income ratio indicates challenges in converting earnings to cash, suggesting operational inefficiencies.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	92.98M	185.83M	405.47M	387.48M	233.67M	171.72M
Gross Profit	67.39M	79.39M	179.42M	147.64M	117.60M	101.87M
EBITDA	-33.36M	-13.55M	64.35M	10.29M	9.00K	3.44M
Net Income	-31.96M	-19.50M	53.66M	-17.93M	-23.00M	-14.92M
Balance Sheet
Total Assets	457.61M	479.66M	482.85M	444.71M	460.99M	454.47M
Cash, Cash Equivalents and Short-Term Investments	247.57M	267.76M	290.41M	110.85M	153.04M	209.40M
Total Debt	14.20M	14.60M	13.50M	12.55M	12.27M	6.13M
Total Liabilities	61.33M	69.32M	52.17M	81.08M	80.46M	55.90M
Stockholders Equity	396.28M	410.34M	430.67M	363.62M	380.53M	398.57M
Cash Flow
Free Cash Flow	-1.74M	23.58M	131.28M	-111.11M	-83.50M	-23.12M
Operating Cash Flow	902.00K	27.37M	141.58M	-47.20M	-35.38M	5.81M
Investing Cash Flow	7.87M	-39.03M	66.15M	21.09M	-5.50M	-14.03M
Financing Cash Flow	-3.83M	-4.18M	-3.02M	-3.83M	-2.82M	92.48M

Orasure Technologies Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 3.02
• 50DMA: Positive
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For OSUR, the sentiment is Positive. The current price of 3.02 is above the 20-day moving average (MA) of 2.91, above the 50-day MA of 2.84, and below the 200-day MA of 3.59, indicating a neutral trend. The MACD of 0.04 indicates Negative momentum. The RSI at 56.17 is Neutral, neither overbought nor oversold. The STOCH value of 58.95 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for OSUR.

Orasure Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
UTMD	79 Outperform	$180.63M	14.72	10.59%	2.19%	-19.92%	-16.22%
PDEX	67 Neutral	$137.49M	15.40	28.29%	―	29.65%	131.78%
STXS	63 Neutral	$190.06M	―	-179.82%	―	1.50%	-20.00%
KRMD	61 Neutral	$157.34M	―	-29.87%	―	19.65%	60.28%
OSUR	57 Neutral	$214.68M	25.27	-7.77%	―	-46.95%	-237.44%
Sector *	51 Neutral	$7.41B	0.32	-61.11%	2.34%	16.99%	1.69%
SMTI	44 Neutral	$249.48M	―	-28.58%	―	34.65%	-128.56%

Orasure Technologies Corporate Events

OraSure Technologies Approves Stock Plan Amendment at Annual Meeting

On May 14, 2025, OraSure Technologies, Inc. held its Annual Meeting of Stockholders, where an amendment to the 2000 Stock Award Plan was approved, increasing the number of shares authorized for grant by 6,000,000 shares. The meeting also included the election of three Class I Directors, the ratification of Grant Thornton LLP as the independent registered public accounting firm for 2025, and an advisory vote on executive compensation, reflecting key governance and operational decisions impacting the company’s future direction.

The most recent analyst rating on (OSUR) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Orasure Technologies stock, see the OSUR Stock Forecast page.

OraSure Technologies Announces CPO Resignation

On May 8, 2025, Kathleen G. Weber announced her resignation as Chief Product Officer of OraSure Technologies, effective June 30, 2025. Her resignation, considered as ‘Good Reason,’ entitles her to severance benefits as per her employment agreement. This change in leadership may impact the company’s operations and strategic direction.

OraSure Technologies Reports Q1 2025 Revenue Decline

On May 7, 2025, OraSure Technologies announced its financial results for the first quarter of 2025, revealing a 45% decrease in total net revenues compared to the same period in 2024, primarily due to a decline in COVID-19 revenues. Despite the revenue drop, the company is focusing on expanding its product portfolio and strengthening customer relationships, with a $40 million stock repurchase program authorized to deliver shareholder value.